Even if we treat the mild untreated population as a preventitive to worsening heart disease
1 billion cap easy on major deal with $JAZZ and we sit back and relax while they spend all phases
IND is the Next Step on the Road to an NDA for DehydraTECH - CBD
Armed with the most recent test results and a history of success with DehydraTECH technology, Lexaria Bioscience Corp (NASDAQ: LEXX) announced last week that it has formally begun the process for an Investigational New Drug application filing with the FDA. The application will list DehydraTECH CBD as a prospective registered pharmaceutical treatment for hypertension.
This is another step to an eventual NDA, provided that ongoing studies continue to show positive results and the company doesn't run into any regulatory hurdles. With both internal and external data on the effectiveness of DehydraTECH, the company may be able to file using the abbreviated 505(b)(2) NDA application, which could significantly speed up timelines.
FDA approval for CBD pharmaceutical treatments is not unprecedented. In 2018, the FDA approved Epidiolex®, a CBD-based pediatric anti-seizure medication. The approved dosage rate for a child weighing 28kg was 140mg, with an increase to 280mg daily for long-term use. DehydraTECH CBD dosages, due to its absorption capabilities, could be significantly less.
DehydraTECH Could Rise to Mega-Drug Status in the BP Space
"If we can sustain these results, we could be looking at mega-drug status ($1 billion per year) in the hypertension market," stated Chris Bunka when asked about projections for the future. "Our goal now is to put together a 4-week study, three doses per day, targeting a sustained drop in blood pressure. That could make us one of the most effective registered pharmaceutical treatments for hypertension in the world, with few if any unwanted side effects."
The process ahead will still take several months, but shareholder optimism is high as DehydraTECH CBD continues to be proven effective in multiple applications. Lexaria's commercial success with their technology has already been established. A pharmaceutical breakthrough in the anti-hypertensive space could launch them into unicorn status.